Evaluation of Adherent Invasive E. Coli Eradication in Adult Crohn Disease
Status:
Unknown status
Trial end date:
2020-04-01
Target enrollment:
Participant gender:
Summary
The primary objective of this trial is to assess whether a 12-week treatment with
Ciprofloxacin and Rifaximin is superior to placebo to obtain endoscopic remission in
adherent-invasive E. coli (AIEC)-colonized patients with ileal Crohn disease (CD), with or
without involvement of the caecum or the right colon.